Vibegron Oral Dosage for Overactive Bladder With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for overactive bladder (OAB) using antimuscarinics are limited by modest efficacy and poor tolerability due to mechanism-based side effects, leading to high discontinuation rates, while existing β3-AR agonists like mirabegron have limitations in selectivity and potential adverse effects.
Innovation Solution
Administering vibegron, a highly selective β3-AR agonist, in doses ranging from 50 mg to 100 mg per day to treat OAB, minimizing side effects and maintaining efficacy by optimizing dosage to reduce Cmax.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimuscarinics are used to treat OAB, then detrusor overactivity is reduced, but side effects such as dry mouth, constipation, and CNS adverse effects increase
Solution Approach 1:
The patent changes the pharmacological parameter from antimuscarinic mechanism to beta-3 adrenergic agonist mechanism, fundamentally altering the drug's mode of action to achieve detrusor relaxation through a different physiological pathway that avoids the harmful side effects of antimuscarinics
2Reliability
If tolterodine or oxybutynin are prescribed, then OAB symptoms are treated, but discontinuation rates increase due to poor tolerability
Solution Approach 1:
The patent changes the pharmacological mechanism from antimuscarinic to beta-3 adrenergic agonist, which improves tolerability and reduces discontinuation rates while maintaining effectiveness in treating OAB symptoms
3Reliability
If mirabegron is used as a beta-3 adrenergic receptor agonist, then detrusor relaxation and increased bladder capacity are achieved, but selectivity limitations and potential adverse effects remain
Solution Approach 1:
The patent optimizes the beta-3 adrenergic agonist structure to achieve superior selectivity (>9000-fold) over beta-1 and beta-2 adrenergic receptors, thereby maintaining detrusor relaxation benefits while minimizing off-target adverse effects on blood pressure and heart rate
4Reliability
If high doses of beta-3 adrenergic agonists are administered, then OAB symptom relief is improved, but adverse effects on blood pressure and heart rate increase
Solution Approach 1:
The patent changes the selectivity parameter of the beta-3 adrenergic agonist to achieve >9000-fold selectivity over beta-1 and beta-2 receptors, allowing effective OAB symptom relief at doses that minimize cardiovascular adverse effects
Solution Approach 2:
The highly selective beta-3 adrenergic agonist acts as a specific mediator that targets only the desired beta-3 receptors in the detrusor muscle, preventing activation of beta-1 and beta-2 receptors that would cause adverse cardiovascular effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Vibegron effectively reduces urinary frequency, urgency, and incontinence episodes with minimal adverse effects on blood pressure and heart rate, demonstrating >9000-fold selectivity for β3-AR over β1-AR and β2-AR, and is well-tolerated across various populations, including those with renal impairment.
Implementation Method 1
Vibegron activates the β3-AR in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity
Data Source
AI summary
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. The present disclosure is also directed to a pharmaceutical unit dosage composition comprising from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron for oral administration.